施普林格·自然等与 ResearchGate 合作引导学术期刊论文分享施普林格·自然等与 ResearchGate 合作引导学术期刊论文分享

2018-05-02 冯丽妃 科学网

记者近日从施普林格•自然集团获悉,该集团和剑桥大学出版社、Thieme 出版社与 ResearchGate 将根据协议,共同促进该学术合作平台在分享文章时能保护作者和出版机构的权利。

记者近日从施普林格?自然集团获悉,该集团和剑桥大学出版社、Thieme 出版社与 ResearchGate 将根据协议,共同促进该学术合作平台在分享文章时能保护作者和出版机构的权利。

作为协议的一部分,ResearchGate 将与出版机构合作,就用户如何及何时可以在该网络上分享在期刊上发表的论文提供更多和更完善的信息,以使其知晓涉及版权保护内容的相关权利。

ResearchGate 会继续在收到出版机构通知后,快速移除侵犯版权的内容。如平台新使用了出版机构原已发表的内容,将给予其更高的可见度。

该协议是去年秋季相关出版机构与 ResearchGate 宣布展开讨论以来的最终结果。这表明人们在分享出版机构的内容方面可以达成合作,也显示了各方对确保科研人员能负责任地获取和使用高质量学术内容的承诺。

施普林格?自然集团首席出版官 Steven Inchcoombe 对此评论说:“施普林格?自然支持科研人员之间分享内容。我们希望自己出版的科研成果能被人发现、获取、理解、使用、再使用和分享,并以此作为出发点,助推新的科学发现。ResearchGate 的用户有 1500 万,因此是我们推动内容分享的重要合作伙伴。

ResearchGate 联合创始人暨首席执行官 Ijad Madisch 说:“对于 ResearchGate 而言,开放科研不仅意味着分享科研论文,而是对之进行讨论并促成有助于研究进展的合作。”

ResearchGate 于 2008 年由内科医生 Ijad Madisch 博士和 S?ren Hofmayer 博士以及计算机专家 Horst Fickenscher 共同创立。公司以连接科学界、将科研开放给所有人作为使命。有 1500 万科研人员通过其网络进行了超过 2.15 亿次联络,在 200 万个项目上展开了科研合作,每天分享超过 50 万个科研进展情况。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1703757, encodeId=b59a1e0375785, content=<a href='/topic/show?id=2312455600d' target=_blank style='color:#2F92EE;'>#学术期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45560, encryptionId=2312455600d, topicName=学术期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f9630567193, createdName=qingrejiedu, createdTime=Sat Aug 18 19:04:00 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080884, encodeId=dc9920808843a, content=<a href='/topic/show?id=61ac588035e' target=_blank style='color:#2F92EE;'>#施普林格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58803, encryptionId=61ac588035e, topicName=施普林格)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Nov 22 05:04:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557778, encodeId=2420155e778ba, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Fri May 04 03:04:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311298, encodeId=30af311298b5, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed May 02 12:33:17 CST 2018, time=2018-05-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1703757, encodeId=b59a1e0375785, content=<a href='/topic/show?id=2312455600d' target=_blank style='color:#2F92EE;'>#学术期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45560, encryptionId=2312455600d, topicName=学术期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f9630567193, createdName=qingrejiedu, createdTime=Sat Aug 18 19:04:00 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080884, encodeId=dc9920808843a, content=<a href='/topic/show?id=61ac588035e' target=_blank style='color:#2F92EE;'>#施普林格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58803, encryptionId=61ac588035e, topicName=施普林格)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Nov 22 05:04:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557778, encodeId=2420155e778ba, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Fri May 04 03:04:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311298, encodeId=30af311298b5, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed May 02 12:33:17 CST 2018, time=2018-05-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1703757, encodeId=b59a1e0375785, content=<a href='/topic/show?id=2312455600d' target=_blank style='color:#2F92EE;'>#学术期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45560, encryptionId=2312455600d, topicName=学术期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f9630567193, createdName=qingrejiedu, createdTime=Sat Aug 18 19:04:00 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080884, encodeId=dc9920808843a, content=<a href='/topic/show?id=61ac588035e' target=_blank style='color:#2F92EE;'>#施普林格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58803, encryptionId=61ac588035e, topicName=施普林格)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Nov 22 05:04:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557778, encodeId=2420155e778ba, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Fri May 04 03:04:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311298, encodeId=30af311298b5, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed May 02 12:33:17 CST 2018, time=2018-05-02, status=1, ipAttribution=)]
    2018-05-04 yangshch
  4. [GetPortalCommentsPageByObjectIdResponse(id=1703757, encodeId=b59a1e0375785, content=<a href='/topic/show?id=2312455600d' target=_blank style='color:#2F92EE;'>#学术期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45560, encryptionId=2312455600d, topicName=学术期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f9630567193, createdName=qingrejiedu, createdTime=Sat Aug 18 19:04:00 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080884, encodeId=dc9920808843a, content=<a href='/topic/show?id=61ac588035e' target=_blank style='color:#2F92EE;'>#施普林格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58803, encryptionId=61ac588035e, topicName=施普林格)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Nov 22 05:04:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557778, encodeId=2420155e778ba, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Fri May 04 03:04:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311298, encodeId=30af311298b5, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed May 02 12:33:17 CST 2018, time=2018-05-02, status=1, ipAttribution=)]
    2018-05-02 1ddf0692m34(暂无匿称)

    学习了.谢谢分享

    0

相关资讯

一篇Nature价值几何?中国科研奖励金的多寡是非

这几年,中国科研论文在现金激励制度下,无论是数量还是质量都在快速上升。但以金钱作为科研事业的驱动力难逃争议。国外学者对这一做法嗤之以鼻:如果科研是对真理的探求,应当和私欲撇清关系。

中国期刊:你能否扔掉“洋拐杖”

近年来,我国科学研究实力增长明显,科技论文综述位居世界第二,从数量上已成论文发表大国。但与之不相称的是,优秀科研成果大多投给了国际期刊,而国内科技期刊发展则相对滞后。

Nature Research开放获取3本新期刊,走高质量精选路线

自然科研(Nature Research)将进一步扩大其开放获取期刊阵容,新增一系列三本跨学科领域高质量、精选型的开放获取期刊,即Communications Biology(《通讯-生物学》)、Communications Chemistry(《通讯-化学》)和Communications Physics(《通讯-物理学》)。这些期刊仅以在线形式出版,发表原作者署名知识共享协议(CC-BY)下的

县级医院论文登上了第一期刊!

近日,全球最具影响力的临床医学类综合期刊之一《新英格兰医学杂志》刊登了浙江宁波北仑区人民医院(浙大一院北仑分院)皮肤科团队的一项研究成果。县级医院的论文“亮相”国际顶级医学期刊,在国内十分少见。那么该论文到底说的是啥?——一种与水痘容易混淆的马尔尼菲蓝状菌病!接诊特殊病例  引发投稿灵感这篇刊登在《新英格兰医学杂志》的文章题为《马尔尼菲蓝状菌感染》,第一作者是宁波北仑区人民医院的皮肤科医

同行双盲评审真的靠谱吗?

“明星效应”不仅存在于娱乐圈,在学术界也不少见。《自然》杂志从2015年3月起为投稿人添加一个选项:双盲同行评审(double-blind review),即投稿人与审稿人之间相互不知道对方姓名和所属机构。然而,由自然出版集团(NPG)发起的最新研究表明,只有1/8的作者选择让审稿人见到匿名论文。

除了Oncotarget,还有哪些5-10分的期刊适合我们?

前段时间,我们整理了可发表中医/药、针灸、meta分析的SCI期刊,今天我们整理了中国人每年的发文量超过10篇的5-10分SCI期刊,供大家参考。